Investing in the future of fertility care

Béa Fertility offers clinical-grade at-home intracervical insemination kits that achieve a 39% pregnancy rate and bridge the gap between natural conception and IVF at a fraction of the cost.

Having received FDA 510(k) clearance in April 2025, Béa is now live across all 50 US states as well as the UK. And the first US pregnancies are being reported, adding to the tally of well over 50 UK babies.

That’s why we’re immensely proud to announce that Béa Fertility, founded by the incredible Tess Isabelle Cosad, is the latest investment from our EIS Fund.

Tess says, "It is incredibly exciting to welcome Angel Academe as investors in Béa Fertility. As the UK’s first female founder EIS fund, their backing reflects a long-standing vision to support women building ambitious companies. We are proud to have them alongside us as we build the future of fertility care."

The Fund invests alongside angels from our network, many of whom have been supporting Béa since their first round. Congratulations all involved!